Rivaroxaban to prevent blood clots in people with urologic cancer on systemic therapy
Tests rivaroxaban against placebo for preventing blood clots in people with genitourinary cancers.
Key facts
- Who runs it
- Ottawa Hospital Research Institute
- Where
- Canada3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 120 people, planned
- Started
- 4 Nov 2024
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Rivaroxaban 10 MG
- Placebo control
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active genitourinary cancer who are starting systemic therapy. It tests low dose rivaroxaban against placebo to prevent blood clots.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Active cancer of the bladder, testis, ureter/renal pelvis, kidney, urethra or penis. People with prostate cancer cannot join.
- Earlier treatment
- Must be starting systemic therapy (chemotherapy, targeted therapy such as tyrosine kinase inhibitors and antiangiogenic therapy, or immunotherapy). The planned treatment must last at least 8 weeks.
Main reasons for not taking part
- Needing blood thinners for another reason for the whole study
- Ongoing bleeding that does not stop, a chronic bleeding disorder, or past conditions with higher bleeding risk such as stroke
- Severe kidney problems (creatinine clearance <30 mL/min) or severe liver disease
- Low platelet count (< 50 x 109/L) or life expectancy under 6 months
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patients who are starting systemic therapy for active GU cancer (bladder, testis, ureter/renal pelvis, kidney, urethral, penile) except for prostate cancer
- Age ≥ 18
- Eligible systemic therapies include chemotherapy, targeted therapies (tyrosine kinase inhibitors and antiangiogenic therapy), and immunotherapies
- Patients must be initiating systemic therapy with a minimum planned treatment duration of 8 weeks
Who cannot take part
- Concomitant use of dual antiplatelet therapy (two antiplatelet medications oncomitantly)
- Concomitant use of strong inducers or inhibitors of CYP3A4 or glycoprotein-P (known interaction with rivaroxaban)
- History of condition at increased bleeding risk including, but not limited to:; cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent bleeding, spontaneous or acquired impairment of hemostasis in the previous 4 weeks
- Known allergies to rivaroxaban
- Ongoing refractory bleeding that may be exacerbated by rivaroxaban
- Severe liver disease (e.g. acute clinical hepatitis, chronic active hepatitis, cirrhosis)
- Chronic hemorrhagic disorder
- Severe renal insufficiency (Creatinine clearance <30 mL/min (defined by Cockcroft-Gault))
- Thrombocytopenia < 50 x 109/L
- Pregnancy (if child bearing age under 50 and sexually active, documentation of use of effective contraception or negative B- HCG is required)
- Anticoagulation (prophylactic or therapeutic dosing) required for another indication for entire duration of study
- Life expectancy under 6 months
- Patient is breastfeeding or lactating
- Inability to adhere to protocol or obtain consent
- Patients may be excluded from the study for other reasons, at the investigator's discretion
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients with genitourinary cancers (ex: bladder, testicular, kidney) are at high risk of developing blood clots if they receive systemic therapy (ex: chemotherapy, immunotherapy). Blood clots cause pain, may require hospitalization and invasive testing, and in some cases cause death. In fact, blood clots are one of the leading causes of death in patients with cancer. Furthermore, patients who develop a blood clot require medication to thin the blood for a prolonged (sometimes indefinite) period of time, and this can disrupt other important cancer treatments. Studies have shown that using low dose blood thinners to prevent blood clots during systemic therapy is effective in some patients with cancer. However very few patients in these studies had genitourinary cancers, therefore physicians in Canada are not sure if recommending blood thinners to patients with genitourinary cancers is useful or safe. Safety is a primary concern because blood thinners may cause bleeding, and patients with genitourinary cancers may have higher risk of bleeding than patients with other types of cancer. The investigators hypothesize that blood thinners are effective and safe for reducing blood clots in patients with genitourinary cancers. The objective of this study is to determine if a large clinical trial testing the effectiveness and safety of low dose blood thinners for preventing blood clots in patients with genitourinary cancers receiving systemic therapy is feasible.
The 2 groups in the trial
- RivaroxabanTreatment being tested
Participants receiving study drug (Rivaroxaban)
Treatment: Rivaroxaban 10 MG
- ControlPlacebo, for comparison
Participants receiving matched placebo
Treatment: Placebo control
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prevention of Thromboembolism With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
- Plain-language title
- Rivaroxaban to prevent blood clots in people with urologic cancer on systemic therapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 12 November 2026